Curis (NASDAQ:CRIS) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Curis (NASDAQ:CRIS) in a report issued on Friday morning,Benzinga reports. They currently have a $17.00 price objective on the biotechnology company’s stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Curis currently has an average rating of “Hold” and a consensus price target of $17.00.

Curis Price Performance

NASDAQ:CRIS opened at $0.77 on Friday. Curis has a 1-year low of $0.75 and a 1-year high of $3.13. The firm has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $1.25. The firm has a market cap of $10.59 million, a PE ratio of -0.65 and a beta of 3.02.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $3.25 million. As a group, sell-side analysts expect that Curis will post -7.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Curis

A number of hedge funds have recently added to or reduced their stakes in CRIS. Jane Street Group LLC lifted its position in shares of Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the last quarter. XTX Topco Ltd bought a new stake in Curis during the 4th quarter worth about $26,000. Warberg Asset Management LLC acquired a new stake in shares of Curis in the third quarter valued at approximately $73,000. Squarepoint Ops LLC increased its position in Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 27,343 shares during the period. Finally, Focused Wealth Management Inc raised its stake in shares of Curis by 33.8% during the third quarter. Focused Wealth Management Inc now owns 79,199 shares of the biotechnology company’s stock worth $131,000 after buying an additional 19,995 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Key Stories Impacting Curis

Here are the key news stories impacting Curis this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $17.00 price target — a highly bullish analyst endorsement that can attract speculative buying given the large upside to the current price. Benzinga
• Positive Sentiment: Company and management continue to advance oncology programs: Curis is targeting full enrollment in its PCNSL registrational study within 12–18 months and is progressing a CLL proof‑of‑concept — milestones that would materially de‑risk and re‑rate the pipeline if achieved. Seeking Alpha
• Neutral Sentiment: Curis issued a fourth-quarter 2025 business update and hosted a conference call — useful for detail and guidance but neutral until management gives clear forward guidance or cash/runway updates. PR Newswire
• Neutral Sentiment: Multiple transcripts of the Q4 2025 earnings call are available (MSN/Yahoo/Seeking Alpha) for investors who want management color; transcripts themselves don’t change fundamentals but help interpret pipeline timelines. MSN Transcript
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.50) missed consensus by $0.07 and revenue of $1.14M missed estimates (~$3.25M). The miss raises near‑term financing and execution risk for a small‑cap biotech with limited revenue. MarketBeat Earnings
• Negative Sentiment: Curis reported an update indicating a pause in the emavusertib trial for certain indications (AML/MDS) — any trial pause increases clinical risk and could delay value realization from that program. Investors should watch for details on reasons for the pause and the path to restart. TipRanks
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous/zero values and NaN changes — current published short interest figures do not present a reliable signal. Monitor official exchange short‑interest reports for clarity.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.